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Abstract
We previously identified EMICORON as a novel G-quad-
ruplex (G4) ligand showing high selectivity for G4 structures
over the duplex DNA, causing telomere damage and inhibition
of cell proliferation in transformed and tumor cells. Here, we
evaluated the antitumoral effect of EMICORON on advanced
models of human colon cancer that could adequately predict
human clinical outcomes. Our results showed that EMICORON
was well tolerated in mice, as no adverse effects were reported,
and a low ratio of sensitivity across human and mouse
bone marrow cells was observed, indicating a good potential
for reaching similar blood levels in humans. Moreover,
EMICORON showed amarked therapeutic efficacy, as it inhibited
the growth of patient-derived xenografts (PDX) and ortho-
topic colon cancer and strongly reduced the dissemination of
tumor cells to lymph nodes, intestine, stomach, and liver.
Finally, activation of DNA damage and impairment of prolif-
eration and angiogenesis are proved to be key determinants of
EMICORON antitumoral activity. Altogether, our results, per-
formed on advanced experimental models of human colon
cancer that bridge the translational gap between preclinical and
clinical studies, demonstrated that EMICORON had an unprec-
edented antitumor activity warranting further studies of EMI-
CORON-based combination treatments. Mol Cancer Ther; 14(11);
2541–51. 2015 AACR.
Introduction
G-quadruplex (G4) ligands are small molecules able to bind to
and stabilize G4 structures widely described at the telomeric ends
of chromosomes (1–6). Interest in the more general therapeutic
significance of G4 has expanded during the past decade including
G4 structures in the promoters of a wide range of genes important
in cell signaling, recognized as hallmarks of cancer. More inter-
estingly, G4 DNA structures have been now visualized in human
cells, corroborating the concept of G4 ligands as therapeutically
susceptible hotspots (6, 7).
Over the past 2 decades, several G4-interacting small mole-
cules, used to act as G4 stabilizers, have been developed with the
aimof identifying potential anticancer therapeutics. In this regard,
growing evidence shows that G4 ligands selectively impair the
growth of cancer cells without affecting the viability of normal
cells pointing out these molecules as possible drug candidates for
future clinical application (8, 9). This evidence gains further
support by the marked antitumoral activity showed by some of
those compounds (BRACO-19, RHPS4, and telomestatin) in
different in vivomodels both as single agents and in combination
with conventional or targeted anticancer agents (10–15). How-
ever, none of the other G4 ligands developed so far has made it
through the drug discovery pipeline due to poor drug-like prop-
erties and/or selectivity profile (16, 17). This has strongly encour-
aged the researchers tomake further efforts in the identification of
G4-binding agents as potential anticancer drugs. In this context,
significant results were obtained by the employment of tetra-
substituted naphthalene diimide compounds as quadruplex-
binding ligands, in inhibiting cancer cell growth both in vitro and
in vivo (18–20). Our group has recently designed a newmolecule,
namely, EMICORON (Fig. 1A), having one piperidinyl group
bound to the perylene bay area, sufficient to guarantee a good
selectivity, and an extended aromatic core able to increase the
stacking interactions with the ending tetrad of the G4. The
subsequent profiling of its biologic properties demonstrated that
this compound is outstandingly potent in inducing selective DNA
damage to telomeres of cancer cells versus normal cells, endowing
with efficient antiproliferative effect on several tumor cell lines at
low micromolar concentrations (21). Moreover, in agreement
with its ability to target theG4 sequence identified in thepromoter
of VEGFR-2 (22), EMICORON can bind toG4 structures through-
out the genome (Fig. 1B), highlighting this drug as a novel
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Figure 1.
Toxicologic profile of EMICORON.
A, structural formula of EMICORON.
B, targeting of G4 structures upon
EMICORON treatment. BJ EHLT
immortalized human fibroblasts were
exposed to 0.5 mmol/L EMICORON for
24 hours and then fixed and co-
immunostained with anti-G4 and anti-
53BP1 antibodies to detect DNA
damage foci. Representative images at
100 magnification are reported.
Enlargements show colocalization
between DNA damage foci, induced by
EMICORON, and G4 structure. C,
histologic analysis of tissue from
untreated or EMICORON-treated mice.
Twenty-four hours after the end of
treatment, mice were euthanized and
tissues placed in 10% buffered formalin
for 24 hours, dehydrated, and
embedded in paraffin. Serial 4-mm-thick
sections were stained with H&E and
analyzed by optical microscope.
Original magnification, 200. D,
average spectra of blood from mice
untreated or treated with doxorubicin
and EMICORN, in the NMR lipid and
lipoprotein spectral area (CPMG
experiments). The regions in which the
differences are more pronounced are
circled or zoomed in. It ismostly the lipid
and lipoprotein profiles that are
affected, especially for what it concerns
the doxorubicin group. E, PCA scores
plot of the CPMG spectral data collected
for each mouse (2 outliers, C4 and D4,
are removed). PC#1, which explains
almost 70% of the total variance, shows
that the control and the EMICORON
groups are behaving similarly, whereas
the doxorubicin one tends to be
different. F, concentration–response
curves of SN-38 and EMICORON in
bone marrow CFU-GM assays. Human
(~) or mouse (~) marrow cells were
continuously exposed for 15 or 13 days,
respectively, to drugs at half-log
intervals covering 7 logs and colonies,
defined as clusters containing 30 or
more cells, were counted and IC50 and
IC90 were determined from
concentration–response curves.
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multitargeting G4-interacting agents warrant further studies
aimed at assessing its antitumoral activity in preclinical models.
Despite many antineoplastic compounds showed favorable
tumor responses in preclinical studies, more than 95% of these
therapeutics failed to confirm efficacy in clinical trials and many
factors are responsible for this high failure rate (23, 24). In
particular, the different sensitivity of murine and human bone
marrow progenitor cells to cytotoxic drugs is critical for the
translation of new compounds from preclinical studies to clinical
application. In fact, only compounds with similar bone marrow
progenitor sensitivity across species may have better potential of
reaching the same blood level in patients as in mice (25). To this
purpose, it has been suggested that the use of bone marrow
colony-forming unit, granulocyte-macrophage (CFU-GM) assay
comparing the toxic effects on bone marrow from animals and
humans could help us identify drugs with good potential for
achieving a therapeutic blood level in patients (26, 27).Moreover,
it is a commonopinion that a furthermajor limitation to translate
cancer research from bench to bedside is the lack of predictive
cancer models. In particular, while ectopic human tumor xeno-
grafts from established cell lines could be useful for a first
assessment of efficacy of new anticancer compounds, the use of
orthotopic models helps us validate compounds against tumor
growth in the site of origin, progression, and metastatic dissem-
ination (28, 29). In this context, genetically engineered mouse
models (GEMM) have become a useful system that, by recapit-
ulating diseases that derive from genetic changes such as cancer,
could predict human responses in the clinic better than xenografts
from established cancer cell lines and could also be a platform for
discovering predictive biomarkers (30). Finally, the recent intro-
duction of patient-derived xenografts (PDX), obtained by
implanting tumor fragments from patients to immunocompro-
mised mice, thus preserving genomic integrity and tumor hetero-
geneity observed in patients, could increase the robustness of drug
discovery studies (31, 32). On the basis of this background, the
aim of this studywas to evaluate the antitumor efficacy of the new
G4 ligand EMICORON on a spectrum of advanced preclinical
models of colon cancer that recapitulate some key points to
be considered for the translatability of experimental findings,
including maintenance of the biologic characteristics of human
cancer in terms of tumor architecture and mutational status,
growth in the origin tissue in the context of a species-matched
tumor stroma microenvironment, and intact immune system.
Materials and Methods
Drugs
N,N-Bis[2-(1-piperidino)-ethyl]-1-(1-piperidinyl)-6-[2-(1-
piperidino)-ethyl]-benzo[ghi] perylene-3,4:9,10-tetracarboxylic
diimide [EMICORON; molecular formula: C52H59N6O4.4HCl;
molecular weight ¼ 977, estimated pKa (piperidine) ¼ 11] was
synthesized as previously described (21) and used as a salt,
specifically hydrochloride, with a good solubility in water.
7-Ethyl-10-hydroxycamptothecin (SN-38, Alexis) and doxorubi-
cin (Ebewe) were also used.
Animals and ethics statement
Six- to 8-week-old male mice CD-1 nude (nu/nu), C57BL/6,
BALB/c (Charles River Laboratories) and NOD/SCID (Harlan
Laboratories), were used. All animal procedures were approved
by the ethics committee of the Regina Elena National Cancer
Institute (CE/534/12) and were in compliance with the national
and international directives (D.L. March 4, 2014, no. 26; directive
2010/63/EU of the European Parliament and of the council;
Guide for the Care and Use of Laboratory Animals, U.S. National
Research Council, 2011).
Human cell lines and PDXs
A90 colon epithelial tumor cell line fromGEMMswas obtained
on October 2013 by E.S. Martin (Dana-Farber Cancer Institute,
Boston, MA). Primary colon cancer cells were obtained by the
mechanical disaggregation of a colon adenocarcinoma specimen
surgically treated at the Regina Elena National Cancer Institute
(Rome, Italy) on January 30, 2013. Both cell lines were not
authenticated. Cells were maintained as monolayer culture in
RPMI-1640 medium supplemented with 10% FCS, L-glutamine,
and antibiotics. PDXs were obtained by the implant in mice of
tumor fragment from a metastatic lymph node of a poorly
differentiated colon carcinoma of a patient at Regina Elena
National Cancer Institute. Briefly, surgical specimens, not
required for histopathologic analysis, were placed in medium
supplemented with antibiotics, diced into 15 to 20 mm3 pieces,
coated in Matrigel, and implanted into NOD/SCID mice by a
small incision and subcutaneous pocket made in one side of the
lower back (33). Aftermass formation inmice (passage 0), tumors
were passed in 4 mice (passage 1) and afterward expanded in 20
mice (passage 2).
CFU-GM assay
According to the protocol described by Kurtzberg and collea-
gues (25), mouse marrow was collected from the long bones
(femur and tibia) of healthy Balb/cmice. Bones were flushedwith
sterile RPMI-1640 supplemented with 5% FBS by using a 27-G
syringe. The resulting cell suspension (1.5  107 cells per
mouse) was collected in a 50-mL conical-bottom tube and kept
in wet ice. Human bone marrow cells (StemCell Technologies)
were prepared according to the vendor protocol. For mouse CFU-
GM assays, mouse bonemarrow cells were cultured inMethoCult
(StemCell Technologies), whereas MethoCult GF medium was
used for humanCFU-GMassays. A total of 4104mouse cells per
plate and 8  104 human cells per plate were set up in duplicate
100-cm2 culture dishes and continuously exposed to EMICORON
or SN-38 at ahalf-log interval concentration covering 7 logs, for 13
days for mouse bone marrow and 15 days for human bone
marrow. Three independent CFU-GM colony formation experi-
ments were performed. Colonies were defined as clusters contain-
ing 30 or more cells.
In vivo toxicological studies
To determine the maximum tolerated dose (MTD) of EMI-
CORON, this compound was freshly dissolved in saline solution
(0.9%) and given per os by oral gavage in healthy mice at doses
from 400 to 800 mg/kg in a single bolus. Then, a chronic
administration of EMICORON at 1:10 of the MTD for 15 days
was evaluated to identify the best scheduling of treatment. Tox-
icity was assessed on the basis of drug-related moribund state,
death, body weight loss, and other signs including mouse behav-
ior andmovement. At the end of treatment, mice were euthanized
and major organs excised for histologic analysis. Each individual
experiment included 3 mice.
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Metabolomics study
BALB/c mice were treated with EMICORON given per os at 15
mg/kg/d per 15 consecutive days or intraperitoneally with doxo-
rubicin at 10 mg/kg in a single treatment, and 24 hours after the
end of treatments, blood was collected into heparinized tubes,
plasma prepared and stored at 80C. Each of the 12 plasma
samples, representing the control group (4) and the 2 treatment
groups (4 EMIþ 4doxorubicin), was thawedon ice and the 5-mm
NMR tubes prepared and analyzed using a standardized and
highly automated procedure on the basis of the guidelines intro-
duced by Beckonert (34). NMR analysis was performed with a
Bruker Avance III 600 spectrometer (Bruker Biospin Gmbh)
operating at 600.13 MHz for protons, equipped with a double
tuned cryo-probe (TCI). Spectrawere acquired at 310Kusing both
the Carr–Purcell–Meiboom–Gill (CPMG) experiment and the
NOESY-presat one (34). To correct for unwanted signal shifts,
the entire dataset was globally aligned with respect to the
a-D-glucose signal around 5.25 ppm using the icoshift algorithm
(35). In total, 24 spectra were acquired and processed using
MATLAB 2013b (The MathWorks Inc.).
Bioluminescence imaging analysis
Primary colon cancer cells and A90 cells were stably transfected
with the PGL2 vector containing the firefly luciferase gene under
control of the SV promoter (Promega). Human xenografts were
imaged using the IVIS imaging system 200 series (Caliper Life
Sciences). Briefly, mice were anesthetized with a combination of
tiletamine—zolazepam (telazol; Virbac) and xylazine (xylazine/
Rompun BAYER) given intramuscularly at 2 mg/kg. Then mice
were injected intraperitoneally with 150 mg/kg D-luciferin (Cal-
iper Life Sciences) and imaged in the supine position 10 to 15
minutes after luciferin injection.Datawere acquired and analyzed
using the Living Image Software version 3.0 (Caliper Life
Sciences).
Antitumor activity
EMICORON was given per os by gavage at 15 mg/kg for 15
consecutive days. In particular, luminescent primary colon cancer
cells were injected (106 cells/mouse) in the spleen of anesthetized
nudemice, and after 30minutes, the spleen was removed. Twelve
days postinjection, when tumor dissemination was evident, treat-
ment started. Real-time tumor dissemination inmice treated with
EMICORON or untreated was monitored using the IVIS imaging
system. Thirty-two days after injection, the mice were sacrificed,
liver and gastrointestinal organs harvested, and imaged. Each
group included 6 mice.
A90 luminescent (A90-LUC) GEMMmurine colon cancer cells
were injected in anesthetized C57BL/6 mice, with a 27-gauge
needle at 105 cells per mouse in 50 mL (50% Matrigel and 50%
medium-free serum), into the rectal mucosa approximately 1 to 2
mm beyond the anal canal, which minimizes the chance of
establishing anal tumors. Mice were treated with EMICORON,
starting fromday 7 after cell injection,when the presence of tumor
in the rectum was observed. Imaging was performed at baseline
(day 7) before the administration of compound, and at days 15
and 23 (2 days after the end of treatment), when mice were
euthanized for ethical reasons and tumor excised for histologic
analysis. Each group included 6 mice.
A cohort of 20 PDXs at passage 2were allowed to grow to about
300 to 350 mm3 before initiation of treatment. Ten mice were
treated with EMICORON and 10 mice were used as control
(untreated). Antitumor efficacy of treatment was assessed by the
following endpoints: (i) percent tumor volume inhibition; (ii)
tumor growth delay, evaluated as T  C, where T and C are the
median times for treated and control tumors, respectively, to
achieve equivalent size; (iii) stable disease, defined as the main-
tenance for at least 3 weeks of the same tumor volume as the start
of treatment; and (iv) increase of mice survival. The animals were
euthanized for ethical reasonswhen tumors reached ameanof 2.5
to 3.0 cm3 in volume or when they became moribund during the
observation period (the time of euthanizationwas recorded as the
time of death).
Histologic and immunohistochemical studies
Paraffin-embedded 4-mm thick sections frommajor organs or
tumors were stained with hematoxylin and eosin (H&E) and
analyzed by optical microscope. The tumor and necrotic areas
and the mitotic index were calculated by morphometric meth-
ods (36). Immunohistochemical analyses were performed by
using the following antibodies: rat monoclonal anti-CD31
(1:100, BD Pharmingen); rabbit monoclonal anti-Ki-67
(1:200, Novus Biologicals); mouse monoclonal anti-phos-
pho-histone H2AX (gH2AX, 1:150, Millipore); anti-cytokeratin
7 (CK7, clone OV-TL 12/30, Dako); anti-cytokeratin 20 (CK20
clone Ks20.8, Dako); and anti-CDX2 (CDX2, clone CDX2-88,
Biocare Medical). The number of tumor vessels per mm2 on
zinc-fixed CD31-stained sections and the proliferation as per-
centage of Ki-67–positive nuclei were evaluated in at least 10
randomly selected fields. Necrotic areas were excluded. The
number of gH2AX-positive cells per mm2 was counted in eight
high-power fields per section.
Immunofluorescence
Treated and untreated cells were fixed in 2% formaldehyde
and permeabilized in 0.25% Triton X-100. Then, cells were
incubated with the following primary antibodies for 2 hours at
room temperature: anti-G4 antibody (1H6 monoclonal anti-
body, P. Lansdorp, ERIBA, University of Groningen, Gronin-
gen, the Netherlands) and anti-53BP1 antibody (Novus Bio-
logical Inc.) and then washed in PBS and incubated with the
following secondary antibodies: TRITC-conjugated goat anti-
rabbit and FITC-conjugated goat anti-mouse (Jackson Immu-
noResearch). Fluorescent signals were recorded by using a Leica
DMIRE2 microscope equipped with a Leica DFC 350FX camera
and elaborated by a Leica FW4000 deconvolution software
(Leica).
Statistical analysis
The Student t test (unpaired, two-tailed) was used for compar-
ing statistical differences. Survival curves of mice were generated
by Kaplan–Maier product-limit estimate, and statistical differ-
ences between the various groups were evaluated by log-rank
analysis with Yates correction (software Primer of Biostatistics,
McGraw-Hill). Differences were considered statistically signifi-
cant when P < 0.05.
Results
EMICORON exhibits a favorable preclinical toxicologic profile
We initially assessed the MTD of EMICORON by treating mice
with high doses of the drug, given by oral gavage in a single
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administration (400, 600, or 800 mg/kg/mouse). We decided to
evaluate this route of administration, as oral administration of
chemotherapeutic agents to patients with cancer in a pill form has
significant advantage over other routes of administration, avoid-
ing complications associated with intravenous or intraperitoneal
dosing and not requiring hospitalization or special care. As
reported in Table 1, the highest dose administered (800 mg/kg)
was very toxic as a bodyweight reduction of 22%was recorded. In
addition, immediately after treatment mice elicited a transient
tachypnea, which passed off in fewminutes.Moreover, during the
first week after treatment, dysentery and dehydration were
reported in mice. These symptoms were not more observed in
the next weeks and mice progressively recovered the initial body
weight. After the injection of the dose of 600mg/kg, a reduction of
about 10% of body weight was reported accompanied by dysen-
tery observed for a couple of days in 1 of 3 treated mice. Finally,
the dose of 400 mg/kg was well tolerated and animals showed
good conditions, as no body weight loss or other symptoms were
observed, thus identifying this one as theMTD.On the basis of our
previous observations showing that to obtain antitumoral effica-
cy, G4-interactive compounds need to be administered for several
days, we fractionated theMTDof EMICORON inmore injections.
Our results (Table 1) demonstrated that while the treatment at 20
mg/kg/d for 15 consecutive days produced amarked body weight
loss, the reduction of the dose at 15 mg/kg/d was free of adverse
effects. The good tolerability of EMICORON was confirmed by
histologic analysis of the major organs of mice treated with this
scheduling. In fact, brain, lung, heart, liver, spleen, kidney, and
femoral bone tissue did not display microscopic difference com-
pared with the mice treated with the vehicle demonstrating that
this scheduling did not produce adverse effects (Fig. 1C).
A pilot metabolomic study using NMR analysis was also con-
ducted in which the potentiality of this new and promising
approach was tested to assess whether the metabolic differences
induced in the mice blood by EMICORON could support the
classical toxicologic approaches. Figure 1D neatly shows that the
averagemetabolome of themice treatedwith EMICORON resem-
bles that of the control group more than the metabolome of the
mice treated with doxorubicin. Indeed, the whole lipid profile
metabolome is significantly suppressed in the mice treated with
doxorubicin, very likely due to the toxicity of this molecule,
whereas the same is not valid for the mice treated with EMI-
CORON,which showa similar lipidprofilewith the control group
(Fig. 1D and Supplementary Fig. S1A and S1B). Further evidence
pointing toward such a result was evidenced by the multivariate
data analysis that highlights the latent variables and summarizes
and describes the characteristics of each mouse (Fig. 1E and
Supplementary Fig. S1C and S1D).
Before moving along the antitumor efficacy studies, we sought
to compare the sensitivity of mouse and human bone marrow to
EMICORON treatment by using the CFU-GM assay. This because
mouse bone marrow is generally less sensitive to many cytotoxic
agents than human bone marrow, allowing in preclinical experi-
ments blood levels that cannot be achieved in patients. Therefore,
compounds having small or no differential in bone marrow
progenitor sensitivity among species may have a better transla-
tional potential. With this aim,mice or human bonemarrow cells
were exposed to different concentration of EMICORON. As con-
trol, the sensitivity of mice and human bone marrow CFU-GM to
the well-studied Top1 inhibitor SN-38 (the active metabolite of
irinotecan) was evaluated. The concentration–response curves are
reported in Fig. 1F, and the ratios of the mouse and human bone
marrowCFU-GMat IC50 and IC90 concentrationswere calculated.
As expected and in agreement with previously published data (25,
26), our results confirm that human bone marrow is more
sensitive to SN-38 than the mouse one, as the ratios mouse/
human for this camptothecin were about 15-fold. Interestingly,
the ratios of mouse/human CFU-GM IC50 and IC90 were about 5-
fold for EMICORON, thus suggesting for this compound a good
potential for reaching similar blood levels in humans as in mice.
EMICORON has a marked antitumoral activity against a colon
cancer PDXs
With the aim of assessing the efficacy of EMICORON in
preclinical models preserving the biologic characteristics of
human colon cancer, in terms of tumor architecture and muta-
tional status, so having a predictive power in the translation into
clinical settings (31), experiments were performed on PDXs.
Histologic and immunohistochemical analysis showed that PDXs
retain morphologic characteristics of the original malignancy
(Fig. 2A). Next, we evaluated the antitumoral activity of the drug
by treating the mice with EMICORON at 15 mg/kg for 15
consecutive days. This scheduling of drug administration has
been chosen on the basis of preliminary data (Supplementary
Table SI). Moreover, according to individual mouse variability in
terms of tumor appearance, we decided to consider eachmouse as
one tumor-bearing entity. Treatment started for eachmousewhen
a tumor mass of about 300 to 350mm3 was evident. As shown in
the Fig. 2B, a progressive increase of tumor mass was observed in
untreated PDXs, whereas EMICORON-treated mice exhibited a
marked reduction of the tumor growth, being all tumors reduced
comparing with the untreated ones. Looking at the overall
response rates (Table 2), EMICORON produced a significant
inhibition of the growth of tumors (64%, P¼ 0.000) and a tumor
growth delay of 13 days. Interestingly, in 2 of the 6mice treated, a
stabilization of the diseasewas observed. Finally, the inhibition of
the tumor growth by EMICORON treatment resulted in a 90%
increase ofmice overall survival with amedian survival time of 63
days (49–76) that was significantly longer (P¼ 0.000) compared
with 33 days (19–41) observed in untreated group (Table 2
and Fig. 2C).
Immunohistochemical analysis, performed 2days after the end
of treatment in tumors sections from untreated and EMICORON-
treated mice, revealed that the strong antitumor efficacy of
Table 1. Identification of MTD of EMICORON in healthy mice
Treatmenta Toxic deaths Body weight loss, % Tachypnea Dysentery Dehydration
(a) 800 mg/kg 0/3 22 Yes Yes Yes
(b) 600 mg/kg 0/3 0 No Yes Yes
(c) 400 mg/kg 0/3 0 No No No
(d) 20 mg/kg/d  15d 0/3 30 No No No
(e) 15 mg/kg/d  15d 0/3 8 No No No
aMice were treated with EMICORON given by oral gavage in a single administration (groups a–c) or fractionated for 15 days (groups d and e).
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Figure 2.
Therapeutic efficacy of EMICORON on PDXs. A, morphologic analysis of the original patient tumor and PDXs. Tumor tissue from ametastatic lymph node of a poorly
differentiated colon adenocarcinoma of the patient (a) and from the PDXs (b) were compared after H&E staining. To determine the morphologic stability
of the xenografts, IHC analysis of CK-7 (c) and CK-20 (d) as markers of the epithelium and of CDX2 (e), the intestinal transcriptional factor, was performed.
Original magnification,400. B, tumor growth curves of untreated (black symbols) and EMICORON-treated (gray symbols) PDXs. Each symbol represents the same
mouse. Six mice for each group were reported. C, survival curves of untreated (black symbol) or EMICORON-treated (gray symbols); D, representative
images of tumor excised from untreated or EMICORON-treated mice, euthanized 2 days after the end of treatment and semiquantitative evaluation of CD31,
Ki-67, and gH2AX immunostainings on paraffin xenopatient-derived tumor sections. Four mice for each group have been evaluated. Four-micrometer-thick tumor
sections were stained with H&E or with anti-CD31, Ki-67, gH2AX antibodies. Original magnification, 400. Data are mean  SD. , P < 0.05;  , P < 0.01.
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EMICORON resulted from the inhibition of the angiogenesis and
the proliferation, in association with the activation of DNA
damage (Fig. 2D). Indeed, in treated tumors, the mean number
of tumor vessels per mm2 was significantly (P < 0.05) reduced to
less than 25 compared with the 35 reported in the untreated
group. At the same time, the percentage of Ki-67–positive nuclei
was significantly (P < 0.05) decreased by about 40% in treated
tumors compared with the controls. Consistently, after treatment
with EMICORON, a significantly (P < 0.01) increased mean
number of gH2AX-positive nuclei/mm2 was observed in com-
parison with untreated ones (16 vs. 10).
EMICORON inhibits the growth of orthotopic colorectal
tumors
The antitumoral efficacy of EMICORON was also evaluated in
an orthotopic model of colon cancer by injecting A90-LUC
GEMM cells in the rectum of mice, and the bioluminescence was
used for noninvasive monitoring of the tumor burden in the
whole mice. This model combines the in vivo drug validation in
the tissue of origin of the primary tumor type in the context of a
species-matched tumor stroma microenvironment and an intact
immune system (30, 37). The quantification of bioluminescence,
shown in Fig. 3A, demonstrated the strong efficacy of EMICORON
in inhibiting the growth of tumor. In fact, from the analysis
performed at day 7 (start of treatment), 16, and 23 (2 days after
the end of treatment), it is evident that while untreated animals
elicited more than 4-fold increase of luciferin signal, the biolu-
minescence inmice treatedwith EMICORONdidnot significantly
increase from the baseline to the endof treatment, thus suggesting
the stabilization of the disease. Figure 3B shows representative
images of untreated and treated mice. Moreover, the marked
difference in tumor mass between untreated and treated mice
was evident by the analysis performed on H&E-stained tumor
sections obtained from euthanized mice at day 23 after tumor
cells injection (Fig. 3C). In particular, from the calculation by
morphometric methods, a significant (P < 0.05) reduction of
tumor area in EMICORON-treated tumor comparedwith untreat-
edwas noticed.Moreover, the very significant (P<0.01) reduction
of mitosis seems to be responsible for the strong antitumoral
activity of EMICORON in this orthotopic model of colon cancer.
Consistent with its ability to target telomeric G4 structures,
EMICORONsignificantly induced the presence of atypicalmitotic
figures, which are indicative of telomere dysfunction.
EMICORON reduces metastatic dissemination of luminescent
primary cultured human colon cancer cells
Because a major problem in the management of human
colon cancer is the treatment of distant metastases, we evalu-
ated the efficacy of EMICORON on the experimental model
of a disseminated disease established after intrasplenic injec-
tion of primary colon cancer cells. In Fig. 4, it is reported the
disease spread in gastrointestinal tract and in liver evaluated at
the start of EMICORON treatment (day 12) and at day 32
(5 days after the end of treatment). Histograms demonstrate
that while more than a 4-fold increase of photons/sec was
observed in untreated group, EMICORON produced the inhi-
bition of the cancer cell dissemination being the luminescence
significantly (P < 0.01) reduced of about 50% compared with
untreated mice. This is evident both for the analysis performed
the in whole mice (A and B) and in organs excised after the
euthanization of animals (C and D).
Discussion
A strong discrepancy between preclinical efficacy and clinical
response is observed for cancer disease, as only 5% of agents
having anticancer activity in preclinical development are licensed,
which is much lower than, for example, 20% for cardiovascular
disease (23, 24). Several are the reasons for this high attrition rate,
including the complexity of the disease and the need for new
clinical trial approaches to improve selection of the best dose, as
well as the application of a biomarker-driven patient subselection
strategy to better identify responsive patients (38). Unquestion-
ably, the preclinical strategies to evaluate novel agents are sub-
optimal and the identification of appropriate preclinical mouse
cancer models remains a major challenge to increase drug devel-
opment efficiency.We recognize that each different type of animal
cancermodel has intrinsic advantages and limitations and that no
single model can capture all the different aspects of tumor growth
characteristics and treatment approaches. Rather, they should be
viewed as a portfolio of sophisticated biologic tools that can be
used optimally in the drug discovery process to answer specific
experimental questions (39, 40). Accordingly, in this article, we
have studied the antitumor efficacy of the new G4 compound
EMICORON on different preclinical models of colon cancer that
may mimic the clinical situation.
A valuable and generally accepted biologic approach to the
study of cancer biology and therapeutics is the ectopic (subcuta-
neously or intramuscularly) implant of tumor cells into syngeneic
(genetically identical) or immunocompromised rodents. Despite
these utilities, ectopic models possess limited pathophysiologic
relevance and clinical predictability due to the nonphysiologic
growth location in thehost, and the absenceof critical stromal and
microenvironmental spatial and paracrine interactions with host
noncancerous cells and tissues, including endothelial cells,
inflammatory cells, and tumor-associated fibroblasts (40, 41).
Amore accurate preclinical representation of human colon cancer
is the orthotopic injection of tumor cells or implant of tumor
tissue. In this article, we have performed a transanal injection of
colon cancer cells, which does not require invasive abdominal
surgery and lead to the growth of a clinically relevant tumor in the
rectum of mice. The translational relevance of this model is
reinforced by the fact that to generate the orthotopic tumor, we
have injected GEMM cells which carry the genetic and phenotypic
signatures of the native cancer, reproduce tumor–stromal
Table 2. EMICORON has therapeutic efficacy against PDXs and GEMMs
Group modela TWIb, % T  Cc, days
Stable disease/
mice treatedd ILSe, %
PDXs 64 13 2/6 90
A90-LUC GEMM 80 n.e. 3/6 n.e.
Abbreviation: n.e., not evaluable.
aMice were treated with EMICORON per os at 15 mg/kg/d for 15 consecutive
days.
bTumor weight inhibition was calculated at the nadir of the effect. Statistical
analysis: PDX treated versus untreated, P ¼ 0.000. A90-LUC GEMM treated
versus untreated, P ¼ 0.002.
cCalculated as the median times for treated (T) and control (C) tumors to reach
the same size (1,000 mg). Statistical analysis: PDX treated versus untreated,
P ¼ 0.001.
dStable disease was defined as themaintenance for at least 2 weeks of the same
tumor weight as the start of treatment.
eIncrease in lifespan. ILS of treated mice was calculated compared their median
survival time with those of untreated mice. Statistical analysis: PDX treated
versus untreated, P ¼ 0.000.
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interactions, and may be predictive of eventual therapeutic
response in human clinical trials (37). From this point of view,
the marked reduction of tumor in the mice rectum after EMI-
CORON treatment, evidenced by the reduction of biolumines-
cence signal and tumor area, as shown by histologic examination,
seems to be very promising for translational purposes.
Because the leading cause of deaths of patients with colon
cancer is the metastatic dissemination and in particular the liver
colonization, it is imperative to assess the therapeutic benefits of a
new compound on experimental models of metastatic disease.
The experiments we performed in a well-established model of
colon dissemination disease, by intrasplenic injection of tumor
cells (42, 43), demonstrated that EMICORON treatment is able to
inhibit the spreading ofmetastasis to both gastrointestinal organs
and liver. The most recent class of preclinical models is PDXs,
where tumor fragments from patients are directly implanted in
immunodeficient mice and then passed directly from mouse to
mouse in vivo. A relevant characteristic of this model is that PDXs
well recapitulate the heterogeneity of tumors in patients and
maintain molecular, genetic, and histologic heterogeneity typical
of tumors of origin through serial passaging in mice. On the
contrary, cell lines, evenwhenpropagated in vivo, are derived from
cancer cells that have adapted to growth outside a natural tumor
microenvironment, resulting in genetic changes that are distinct
from the genetic stress imposed on tumors in patients (44).
Notwithstanding some limitations due to the drift of stromal
components from human to mouse, PDXs represent a great
challenge for oncology drug development, if viewed as comple-
mentary to other preclinical models (45). In this study, we have
demonstrated that PDXs showed fidelity to the original tumor, as
theymaintain themorphologic features of a poorly differentiated
colon adenocarcinoma and conserved the sameKRASmutation in
the region of exon 2 of codon 12, observed in tumor of patient.
Interestingly, while patient was insensitive to chemotherapy,
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Figure 3.
Antitumor activity of EMICORON on
orthotopic model of colon cancer.
A90-LUC colorectal murine cells were
injected in the rectal mucosal surface
of mice and EMICORON was
administered from days 7 to 21 after
tumor cell injection. The real-time
tumor growth was monitored by
optical imaging. A, histogram reports
bioluminescence in tumors from
untreated and treated groups. B,
representative images of untreated
and EMICORON-treated mice. C, two
days after the end of treatment (day
23), mice were euthanized, tumors
excised, and after staining with H&E,
tumor area andmitotic index permm2
was evaluated. In the same samples,
the number of atypical mitosis was
scored at 63 magnification.
Representative images of tumor area
at 10 original magnification and
mitosis at 20 and 63 original
magnification. Data are mean  SD
from 6 mice per group.
 , P < 0.05; , P < 0.01.
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EMICORON treatment was very effective against PDXs as resulted
by the strong inhibition of tumor growth, the stabilization of the
disease in 2 of 6 mice treated and the significant improvement of
the overall survival of mice.
Notably, antitumor efficacy observed at the dose of 15 mg/kg
was consistent with the safety of EMICORON treatment, as no
body weight loss or toxic deaths were observed in mice and
histologic analysis onmajor organs confirmed the lack of adverse
effects. Moreover, a further evidence of the good tolerability of
EMICORON is highlighted by the metabolomic analysis. Indeed,
even EMICORON has an impact on the mouse metabolome that
can be further studied with a more systematic metabolomic
approach, it results rather clear that the effects caused by EMI-
CORON are less pronounced than those observed with doxoru-
bicin, making this drug a good candidate for low toxicity. How-
ever, given the cardiovascular off-target effects (interaction with
the human recombinant b2 adrenergic receptor and M1, M2 and
M3 muscarinic receptors, together with a high inhibition of the
hERG) observed with the G4 ligand RHPS4 compromising the
acceptability of this drug as a clinical candidate (16), data on this
are essential before moving EMICORON into clinic. In this
context, pharmacokinetic data, including time course analysis of
drug absorption, distribution, metabolism, and excretion will be
relevant, especially as the compound does not have the appear-
ance of a conventional drug and will permit us to improve the
therapeutic efficacy of the drug and have more information that
can justify the very high apparent MTD dose.
A key point in drug development from preclinical studies to
clinical application is the use of optimal dose, but a frequent
observation is that murine bone marrow progenitors are less
sensitive to compounds compared with human ones. This means
that the drug blood levels achieved in mice producing preclinical
efficacy cannot be reached in patients, thus resulting in the failure
of clinical trials. On the basis of these observations, it has been
suggested that compounds with little differential in bonemarrow
sensitivity across species may have greater potential for reaching
similar blood levels in patients as inmice (25). So, on the basis of
the CFU-GM assay developed by Pessina and colleagues (46) and
validated in several studies (26, 47, 48), we demonstrated that the
mouse bone marrow is only about 5-fold less sensitive than
human bone marrow, thus suggesting that EMICORON could
reach a similar blood levels in humans as in mice. This is in line
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Figure 4.
Effect of EMICORON treatment on a
model of colon cancer disseminated
disease. Luminescent primary colon
cancer cells were injected in the spleen
of immunosuppressed mice (n ¼ 12).
Real-time tumor dissemination was
monitored by the imaging system.
A, histograms report bioluminescence
in mice untreated (6 mice) or treated
with EMICORON (6 mice) at day 12
after tumor cell injection (start of
treatment) and at day 32 after tumor
cell injection. B, representative images
of mice. C, at day 32, mice were
sacrificed; organs were harvested and
acquired using the imaging system.
D, representative images of liver and
gastrointestinal organs. Bars, mean
values  SD.  , P < 0.01.
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with the absence of any damage in the major organs of mice
treated with the drug.
In conclusion, while the ultimate proof of concept for efficacy
and safety of novel oncology therapeutics lies in humans, our
results, performed in relevant preclinical model of colon cancer,
support further investigation of EMICORON antitumor efficacy,
possibly in combination with standard chemotherapeutics or
targeted compounds.
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